Lymphoma Coalition publishes research on the experiences of patients and care partners based on learnings from the Global Patient Survey on Lymphomas and CLL (GPS) and other projects.
It is imperative the issues raised by patients and their care partners through the biennial survey, interviews, focus groups and other initiatives are conveyed to the medical and research communities to improve care moving forward.
[{"id":39981,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/mapping-therapy-related-side-effects-in-relapsed-large-b-cell-lymphoma\/","name":"mapping-therapy-related-side-effects-in-relapsed-large-b-cell-lymphoma","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/Abstract1-3.png","alt":""},"title":"Side-Effects in Relapsed Large B-Cell Lymphoma - 2022 Global Patient Survey","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Dec 12, 2023","dateGMT":"2023-12-12 17:21:00","modifiedDate":"2025-10-14 14:51:30","modifiedDateGMT":"2025-10-14 14:51:30","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/sideeffects\/\" rel=\"category tag\">Side Effects<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/treatment\/\" rel=\"category tag\">Treatment<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/\" rel=\"category tag\">Treatment & Side Effects<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/sideeffects\/\" rel=\"category tag\">Side Effects<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/treatment\/\" rel=\"category tag\">Treatment<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/\" rel=\"category tag\">Treatment & Side Effects<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":3,"sec":57},"status":"publish","excerpt":"Presented at the 65th ASH Annual Meeting and Exposition\n\nfrom 9-12 December 2023, in San Diego, California. The identification of side-effects associated with a particular therapy relies on univariable assessments of incidence across treatment arms. While this approach serves to set the groundwork for the establishment of causation, it is suboptimal when the incidence is small or when novel therapeutics with limited deployment are being examined.\n\nIn this study, we used a multivariate approach to aggregate multiple symptoms in order to segment our sample into those who had differing degrees of side-effect incidence. We used the resultant strata to examine the use of various therapies."},{"id":40010,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/barriers-to-clinical-trial-information-in-relapsed-refractory-lymphoma-patients-post-sct\/","name":"barriers-to-clinical-trial-information-in-relapsed-refractory-lymphoma-patients-post-sct","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/Demographic-Barriers-to-Clinical-Trial-Information-in-RR-Lymphoma-Patients-PostSCT.png","alt":""},"title":"Demographic Barriers to Clinical Trial Information in R\/R Lymphoma Patients Post-SCT","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Apr 26, 2023","dateGMT":"2023-04-26 17:38:00","modifiedDate":"2025-10-14 14:54:06","modifiedDateGMT":"2025-10-14 14:54:06","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/psychosocial\/\" rel=\"category tag\">Psychosocial<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/relapserefractory\/\" rel=\"category tag\">Relapse\/Refractory<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/psychosocial\/\" rel=\"category tag\">Psychosocial<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/relapserefractory\/\" rel=\"category tag\">Relapse\/Refractory<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":3,"sec":46},"status":"publish","excerpt":"Presented at the 49th Annual European Society for Blood and Marrow Transplantation (EBMT) meeting, in Paris France, 22-26 April 2023. Lymphoma Coalition (LC) supports almost 90 patient organizations across more than 50 countries. LC\u2019s overarching goal is to facilitate a community of patient organizations supporting efforts to help patients with lymphoma receive optimal care and support.\n\nStem Cell Transplant (SCT) and clinical trials involving new treatments provide increased opportunities for longer-lasting remission in patients with lymphoma with relapsed or refractory disease. However, not all patients are given information or the opportunity to access clinical trials.\n\nThis study investigates the potential socioeconomic barriers to receiving information on clinical trials or the opportunity to participate in them for patients with lymphoma who have previously received SCT."},{"id":39976,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/an-assessment-side-effect-incidence-for-those-receiving-car-t-versus-other-treatments-in-the-setting-of-relapsed-or-refractory-disease\/","name":"an-assessment-side-effect-incidence-for-those-receiving-car-t-versus-other-treatments-in-the-setting-of-relapsed-or-refractory-disease","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/assessment-side-effect-incidence-cart-abstract.png","alt":""},"title":"Side-Effect Incidence in CAR-T vs. Other Treatments in R\/R Disease","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Feb 17, 2023","dateGMT":"2023-02-17 17:16:00","modifiedDate":"2025-10-14 15:05:58","modifiedDateGMT":"2025-10-14 15:05:58","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/sideeffects\/\" rel=\"category tag\">Side Effects<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/\" rel=\"category tag\">Treatment & Side Effects<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/sideeffects\/\" rel=\"category tag\">Side Effects<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/\" rel=\"category tag\">Treatment & Side Effects<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":2,"sec":55},"status":"publish","excerpt":"Presented at the 6th EBMT-EHA CAR-T Cell Meeting from 15-17 February 2023 in Valencia, Spain. Lymphoma Coalition (LC) supports over 90 member organizations across 54 countries. LC\u2019s overarching vision is equity in lymphoma outcomes across borders.\n\nIn the setting of relapsed\/refractory lymphoma, patients will have experienced at least one line of therapy and will likely be facing another to prolong life. CAR-T is gaining traction as a novel approach to treat relapsed\/refractory disease. Due to the novelty of CAR-T use, a knowledge gap exists regarding some of the rarer side-effects associated with CAR-T."},{"id":40034,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/psychosocial-experiences-in-relapsed-refractory-dlbcl-car-t-vs-other-therapies\/","name":"psychosocial-experiences-in-relapsed-refractory-dlbcl-car-t-vs-other-therapies","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/Abstract_96-Psychosocial-CART-vs-non-CART-1-1.png","alt":""},"title":"Psychosocial Experiences in Relapsed\/Refractory DLBCL: CAR-T vs. Other Therapies","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Feb 11, 2022","dateGMT":"2022-02-11 18:02:00","modifiedDate":"2025-10-14 15:07:41","modifiedDateGMT":"2025-10-14 15:07:41","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/psychosocial\/\" rel=\"category tag\">Psychosocial<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/relapserefractory\/\" rel=\"category tag\">Relapse\/Refractory<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/psychosocial\/\" rel=\"category tag\">Psychosocial<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/relapserefractory\/\" rel=\"category tag\">Relapse\/Refractory<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":2,"sec":41},"status":"publish","excerpt":"Presented during the \u201cBest Abstract Session\u201d at the 5th European CAR-T Cell Meeting in Rotterdam, The Netherlands, February 9-11. Chimeric antigen receptor T-cell (CAR-T) therapy continues to expand as a treatment option for patients with relapsed\/refractory diffuse large B cell lymphoma (DLBCL). This study provides insight into the psychosocial experiences of patients with relapsed and refractory DLBCL treated with CAR-T compared to other therapies."}]